sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 disclosure concerning Avadel Pharmaceuticals plc. This disclosure is part of the requirements set by the Irish Takeover Panel under Rule 8.3 of the 1997 Takeover Panel Act. As of January 8, 2026, Vanguard holds 5,869,355 ordinary shares of Avadel, representing 6.03% of the company's shares.
The document details Vanguard's interests and short positions in Avadel's ordinary shares, alongside recent transactions involving these securities. Specifically, the company purchased 4,233 shares and sold 285 shares, all at a price of USD 21.48 per share. No cash or stock-settled derivatives or agreements to purchase or sell were disclosed beyond these outright share transactions.
The filing also clarifies that Vanguard has no indemnity, option arrangements, or understandings related to Avadel's securities
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.